DiaMedica Therapeutics Inc.

NasdaqCM:DMAC 주식 보고서

시가총액: US$178.8m

DiaMedica Therapeutics 미래 성장

Future 기준 확인 0/6

DiaMedica Therapeutics 의 수익은 연간 11.3% 감소할 것으로 예상되는 반면, 연간 수익은 69.8% 로 증가할 것으로 예상됩니다. 69.8% 연간. EPS는 연간 7.7% 만큼 쇠퇴할 것으로 예상됩니다.

주요 정보

-11.3%

수익 성장률

-7.7%

EPS 성장률

Biotechs 수익 성장28.4%
매출 성장률69.8%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트15 Nov 2024

최근 미래 성장 업데이트

Recent updates

Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

Nov 23
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

May 16
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Jan 12
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold

Jul 06

We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

Jun 16
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Jan 04
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.

Nov 05

DiaMedica: Undercovered Stroke Drug Company With Decent Data

Jun 13

We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

May 01
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?

Feb 13
Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?

We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn

Jan 09
We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn

DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

수익 및 매출 성장 예측

NasdaqCM:DMAC - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026N/A-39-39-342
12/31/2025N/A-34-34-344
12/31/2024N/A-24-24-224
9/30/2024N/A-22-19-19N/A
6/30/2024N/A-20-20-20N/A
3/31/2024N/A-19-20-20N/A
12/31/2023N/A-19-19-19N/A
9/30/2023N/A-18-18-18N/A
6/30/2023N/A-17-15-15N/A
3/31/2023N/A-15-13-13N/A
12/31/2022N/A-14-12-12N/A
9/30/2022N/A-13-12-12N/A
6/30/2022N/A-14-12-12N/A
3/31/2022N/A-13-12-12N/A
12/31/2021N/A-14-12-12N/A
9/30/2021N/A-15-13-12N/A
6/30/2021N/A-14-12-12N/A
3/31/2021N/A-13-11-11N/A
12/31/2020N/A-12-9-9N/A
9/30/2020N/A-11-8-8N/A
6/30/2020N/A-10-7-7N/A
3/31/2020N/A-10-9-9N/A
12/31/2019N/A-11-9-9N/A
9/30/2019N/A-10-9-9N/A
6/30/20191-9-10-10N/A
3/31/20191-8-8-8N/A
12/31/20181-6-6-6N/A
9/30/20181-5-5-5N/A
6/30/2018N/A-4N/A-4N/A
3/31/2018N/A-4N/A-4N/A
12/31/2017N/A-4N/A-4N/A
9/30/2017N/A-4N/A-4N/A
6/30/2017N/A-4N/A-4N/A
3/31/2017N/A-3N/A-3N/A
12/31/2016N/A-2N/A-3N/A
9/30/2016N/A-2N/A-2N/A
6/30/2016N/A-2N/A-2N/A
3/31/2016N/A-1N/A-2N/A
12/31/2015N/A-2N/A-2N/A
9/30/2015N/A-2N/A-1N/A
6/30/2015N/A-2N/A-2N/A
3/31/2015N/A-3N/A-3N/A
12/31/2014N/A-5N/A-4N/A
9/30/2014N/A-5N/A-4N/A
6/30/2014N/A-6N/A-5N/A
3/31/2014N/A-7N/A-5N/A

애널리스트 미래 성장 예측

수입 대 저축률: DMAC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: DMAC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: DMAC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: DMAC 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: DMAC 은(는) 내년에 수익이 없을 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: DMAC 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견